Xi'an Mokemei Biotechnology (revision 33)
Old revision·18:41, 16 Aug 2025·PrimarySrcPatia
| Xi'an Mokemei Biotechnology Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Xi'an Mokemei Biotechnology Co., Ltd. |
| Trading name | MKM |
| Other designations | MKM Biotech, Xi'an Mokemei Biotechnology |
| Identity | |
| Founded | 2016 |
| Headquarters | Xi'an, China |
| Industry | Research-compound supply |
| Shop domain | Visit MKM |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Xi'an Mokemei Biotechnology Co., Ltd. (trading as MKM; mokemeibiotechnology.com) is a research-compound supplier trading as MKM from Xi'an, Shaanxi, China, incorporated in 2016, distributing research peptides, SARMs and raw materials with batch documentation.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2016 in Xi'an, the organisation operates from the largest city in north-western China and, like the Chengdu entity, from outside the coastal manufacturing belt.[1] Xi'an has a substantial pharmaceutical and botanical-extract sector, and the organisation's catalogue includes extract-derived materials alongside synthetic peptides, which is unusual among the entities covered here.[2]
The documentary base is the registry record and the organisation's own material, plus purchaser reports. No independent coverage has been identified.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports describe conventional vialled lyophilised material with a batch certificate.[5] Reported certificate content has been variable within this set — some reporting purity and water, others purity alone — and two submissions noted a certificate whose lot identifier did not correspond to the vial label, which is a traceability failure rather than a quality finding but is recorded here because it is the kind of discrepancy this wiki exists to document.[5]
That observation rests on two reports and is not generalisable. It is stated because omitting it would be a selection decision, not because two reports establish a pattern.
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide | Certificate, variable content |
| Research peptides | Repair and secretagogue peptides | Certificate, variable content |
| Extract-derived materials | Botanical extracts, standardised | Certificate, assay basis unclear |
| SARMs and raw materials | Bulk | Certificate, purity only |
The extract-derived listings sit in a different analytical world from synthetic peptides: a standardised extract is characterised by marker-compound assay rather than by area percent of a single species, and a purity figure on such a material means something different.[2]
Independent testing record
[edit]Submitted reports on MKM material to July 2026 cover the incretin range and a small number of repair peptides. Reported area percent figures have been high in most cases, with two reports in the set falling below the accompanying certificate by more than a percentage point.[5]
A discrepancy of that size between an independent report and a certificate has several innocent explanations — different columns, different integration parameters, different reference standards, sample handling between purchase and testing — and does not establish that either figure was wrong. It is recorded because inflated purity claims are a documented failure mode in this sector and a discrepancy is the only observable that would indicate one.[5]
Reception
[edit]The PeptidePedia tally records 776 self-reported submissions to July 2026 — below the median for the supplier articles. Recurring complaints concern certificate consistency and the lot-matching discrepancies noted above; recurring positive themes are price and catalogue breadth.[4] Self-selected; reception rather than quality.[4]
See also
- Certificate of analysis
- Third-party testing
- Area percent purity
- Peptide content
- Research use only
- Peptide supply chain
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ a b c PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c d Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.